Abstract
Objectives
To define high risk prostate cancer using prostate cancer specific mortality as the key outcome metric.
Methods
Data from two population based cohorts of men from Connecticut who were diagnosed with localized prostate cancer were analyzed to determine the natural history of prostate cancer and the impact of treatment on long term survival.
Results
Men with Gleason 7–10 prostate cancer and a potential survival of 10 years have a high risk of dying from their disease if they elect active surveillance. Surgery appears to offer an improved survival for these men when compared to radiation therapy or observation. Men diagnosed with Gleason 6 tumors in the contemporary era are more likely to harbor low risk prostate cancer when compared to historical series.
Conclusions
Our studies confirm that high risk prostate cancer is best identified by Gleason score 7–10, but challenge the concept that men with high-grade disease are less likely to benefit from radical surgery. Men who have rising PSA values following treatment with either surgery or radiation have residual prostate cancer and are at very high risk of dying from prostate cancer within 10 years.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21:2163–2172
Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55–74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980
Albertsen PC, Hanley JA, Fine J (2005) 20–year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101
Albertsen PC, Hanley JA, Penson DF, Barrows F, Fine J (2007) Thirteen-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 177:932–936
Epstein JI (2000) Gleason 2–4 adenocarcinoma of the prostate on needle biopsy. Am J Surg Pathol 24:477–478
Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PDH, Sanders MM, Fine J (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248–1253
Albertsen PC, Hanley JA, Penson DF, Fine J (2004) Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 171:2221–2225
Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO (2004) Natural history of early, localized prostate cancer. JAMA 291:2713–2719
Bill-Axelson A, Holmberg L, Ruutu M et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977–1984
Chism DB, Hanlon AL, Tronsco P, Al-Saleem T, Horowitz EM, Pollack A (2003) The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 56:1241–1247
Smith EB, Frierson HF, Mills SE et al. (2002) Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years. Cancer 94:2282–2287
Schellhammer P, Moriarty R, Bostwick D et al. (2000) Fifteen year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Urology 56:436–439
Pound DR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597
Conflict of interest statement
There is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Albertsen, P.C. The face of high risk prostate cancer. World J Urol 26, 205–210 (2008). https://doi.org/10.1007/s00345-008-0254-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-008-0254-3